Lidocaine

Cancer-Related Condition

National and Kapodistrian University of AthensSmall moleculePhase 2/3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Cancer-Related Condition cohort.

Asset / Sponsor	Phase	Rating
Oxycodone Deventer Ziekenhuis	Phase 4	BB
Nepenthe Instituto Nacional de Cancer, Brazil	Phase 3	BB
Ethylicum Sindh Institute of Urology and Transplantation	Phase 4	BB
Dexasone Montefiore Medical Center	Phase 4	BB
Tanezumab Pfizer	Phase 3	BB

View all 20 →

Same molecule, other indications

Lidocaine is also rated in:

peripheral neuropathyActive

BBB

Indicative · Phase 4

79 / 100

postherpetic neuralgiaDormant

BBB

Indicative · Phase 4

78 / 100

post-operative pain, non-human animalActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.